Free shipping
on orders over $300
Damage protection
replacement guarantee
Secure checkout
3D Secure
Certificate of Analysis
Third-party tested · ISO/IEC 17025 accredited
99%
purity
✓ Passed full QC panel
- Variant
- Tirzepatide · 30 mg
- Lot #
- TBD
- Labeled
- 30 mg
- Tested
- —
Full QC panel
- Purity (HPLC)
- 99%
- Net Peptide Content
- Pass
- Identity (HPLC-MS)
- Confirmed
- Heavy Metals (ICP-MS)
- Not detected
- Sterility
- No growth
- Endotoxin (LAL)
- Within limits
Purity, lot and tested date are per-lot; remaining QC rows are representative — exact values on the CoA.
Compound Information
Chemical and structural properties
Chemical identity verified via NIH PubChem · biological targets characterized from the peer-reviewed literature.
Molecular profile
Structure
- CAS Number
- 2023788-19-2
- Molecular Formula
- C225H348N48O68
- Molecular Weight
- 4813 g/mol
- Sequence
- (see COA)
- Type
- Research peptide
- PubChem
- CID 156588324 ↗
Biological targets
Interactions
- Primary target
- GIP and GLP-1 receptors (dual agonist)
- Pathway
- GIPR / GLP-1R–cAMP incretin signaling
- Mechanism
- Dual GIP / GLP-1 receptor agonist
- Research area
- Glycemic control, metabolic research
Physical properties
Handling & Storage
- Appearance
- White lyophilized powder
- Solubility
- Soluble in sterile water; reconstitute prior to use
- Storage
- 2-8 deg C, protect from light
- Country of origin
- USA
Sources & References
Peer-reviewed research
Indexed in NIH PubMed. Provided for research context; not a claim of clinical outcome.
CARDIOVASCULAR DIABETOLOGY
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
2022 · PMID 36050763
Nauck MA et al.
View Source ↗FRONTIERS IN ENDOCRINOLOGY
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
2024 · PMID 39114288
Liu QK
View Source ↗LANCET (LONDON, ENGLAND)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
2021 · PMID 34186022
Rosenstock J et al.
View Source ↗JCI INSIGHT
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
2020 · PMID 32730231
Willard FS et al.
View Source ↗DIABETOLOGIA
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
2022 · PMID 35579691
Karagiannis T et al.
View Source ↗
⚠ Important research notice
PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.
All the research peptides you need, with the peace of mind at your fingertips.
Stay Connected with Aminologix
Be the first to receive exclusive discount codes, new product launches, special offers, educational content, research updates, and company news. No spam. Unsubscribe anytime.